Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study

Imagem de Miniatura
Arquivos
art_PAIS_Heterogeneity_of_Cerebrospinal_Fluid_Biomarkers_Profiles_in_Individuals_2021.PDF (376.09 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IOS PRESS
Autores
VALE, Vagner do
Citação
JOURNAL OF ALZHEIMERS DISEASE, v.81, n.3, p.949-962, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Decreased cerebrospinal fluid (CSF) concentrations of the amyloid-beta (A beta), along with increased total (T-tau) and phosphorylated tau protein (P-tau), are widely accepted as core biomarkers of Alzheimer's disease (AD) pathology. Nonetheless, there are a few remaining caveats that still preclude the full incorporation of AD biomarkers into clinical practice. Objective: To determine the frequency of clinical-biological mismatches in a clinical sample of older adults with varying degrees of cognitive impairment. Methods: 204 participants were enrolled for a cross-sectional assessment and allocated into diagnostic groups: probable AD (n = 60, 29.4%); MCI (n = 84, 41.2%); or normal cognition (NC, n = 60, 29.4%). CSF concentrations of A beta(42), T-tau, and (181)Thr-P-tau were determined, and A beta(42)/P-tau ratio below 9.53 was used as a proxy of AD pathology. The AT(N) classification was further used as a framework to ascertain the biological evidence of AD. Results: The majority (73.7%) of patients in the AD group had the A beta(42)/P-tau ratio below the cut-off score for AD, as opposed to a smaller proportion in the MCI (42.9%) and NC (23.3%) groups. In the latter, 21 subjects (35%) were classified as A+, 28 (46.7%) as T+, and 23 (38.3%) as N+. In the AD group, 66.7% of the cases were classified as A+, 78.3% as T+, and 80% as N+. Conclusion: Analysis of CSF biomarkers was able to discriminate between AD, MCI, and NC. However, clinical-biological mismatches were observed in a non-negligible proportion of cases.
Palavras-chave
Alzheimer's disease, biomarkers, cerebrospinal fluid, dementia, mild cognitive impairment
URI
https://observatorio.fm.usp.br/handle/OPI/41554
Referências
  1. Ala TA, 2000, NEUROLOGY, V54, P843, DOI 10.1212/WNL.54.4.843
  2. Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
  3. American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
  4. Army Individual Test Battery, 1944, MAN DIR SCOR
  5. Avila R, 2016, ARQ NEURO-PSIQUIAT, V74, P138, DOI 10.1590/0004-282X20150200
  6. Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012
  7. Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753
  8. BLENNOW K, 1995, NEURODEGENERATION, V4, P187, DOI 10.1006/neur.1995.0023
  9. Boccardi M, 2017, NEUROBIOL AGING, V52, P141, DOI 10.1016/j.neurobiolaging.2017.01.021
  10. Costerus JM, 2018, LANCET NEUROL, V17, P268, DOI 10.1016/S1474-4422(18)30033-4
  11. Cummings J, 2019, ADV EXP MED BIOL, V1118, P29, DOI 10.1007/978-3-030-05542-4_2
  12. Dhiman K, 2019, CELL MOL LIFE SCI, V76, P1833, DOI 10.1007/s00018-019-03040-5
  13. Drachman DA, 2014, ALZHEIMERS DEMENT, V10, P372, DOI 10.1016/j.jalz.2013.11.003
  14. Dubois B, 2018, J ALZHEIMERS DIS, V62, P1059, DOI 10.3233/JAD-170536
  15. Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0
  16. Duits FH, 2016, ALZHEIMERS DEMENT, V12, P154, DOI 10.1016/j.jalz.2015.08.003
  17. Eisenstein M, 2011, NATURE, V475, pS20, DOI 10.1038/475S20a
  18. FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351
  19. Forlenza Orestes V, 2015, Alzheimers Dement (Amst), V1, P455, DOI 10.1016/j.dadm.2015.09.003
  20. Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
  21. FULD PA, 1980, CORTEX, V16, P255, DOI 10.1016/S0010-9452(80)80061-X
  22. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  23. Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6
  24. HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
  25. Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923
  26. Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
  27. Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0
  28. Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004
  29. Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062
  30. JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742
  31. Knopman DS, 2013, ANN NEUROL, V73, P472, DOI 10.1002/ana.23816
  32. Lobo A, 2000, NEUROLOGY, V54, pS4
  33. Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56
  34. Mattsson N, 2015, BRAIN, V138, P772, DOI 10.1093/brain/awu367
  35. McRae-McKee K, 2019, ALZHEIMERS DEMENT, V15, P1348, DOI 10.1016/j.jalz.2019.07.010
  36. Mintun MA, 2006, NEUROLOGY, V67, P446, DOI 10.1212/01.wnl.0000228230.26044.a4
  37. MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413
  38. Okello A, 2009, NEUROLOGY, V73, P754, DOI 10.1212/WNL.0b013e3181b23564
  39. Pais M, 2020, BRAZ J PSYCHIAT, V42, P431, DOI 10.1590/1516-4446-2019-0735
  40. Perrin RJ, 2009, NATURE, V461, P916, DOI 10.1038/nature08538
  41. Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303
  42. Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x
  43. Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
  44. Rohn TT, 2013, INT J MOL SCI, V14, P14908, DOI 10.3390/ijms140714908
  45. ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698
  46. Sala A, 2020, MOL PSYCHIATR, DOI 10.1038/s41380-020-00950-w
  47. Sampaio SG, 2009, ACTA MEDICA PORT, V22, P571
  48. Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142
  49. Schneider JA, 2009, ANN NEUROL, V66, P200, DOI 10.1002/ana.21706
  50. Schott Jonathan M, 2012, Pract Neurol, V12, P358, DOI 10.1136/practneurol-2012-000315
  51. Shaw LM, 2018, ALZHEIMERS DEMENT, V14, P1505, DOI 10.1016/j.jalz.2018.07.220
  52. Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610
  53. Sierra-Rion A, 2016, NEURODEGENER DIS, V16, P69, DOI 10.1159/000439258
  54. Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
  55. Suemoto CK, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002267
  56. Vogelgsang J, 2019, ASN NEURO, V11, DOI 10.1177/1759091419845524
  57. Wallin AK, 2010, NEUROLOGY, V74, P1531, DOI 10.1212/WNL.0b013e3181dd4dd8
  58. WECHSLER D, 1981, CONTEMP EDUC PSYCHOL, V6, P82, DOI 10.1016/0361-476X(81)90035-7
  59. WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940
  60. World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
  61. Zhou B, 2009, J ALZHEIMERS DIS, V18, DOI 10.3233/JAD-2009-1124

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27